What You Can Expect in 2026?
Cell therapy is accelerating toward commercialization faster than most PD teams are prepared for. FDA rejections are consistently tied to process gaps, not clinical failures. The window to get ahead of this is now.
At the 5th Process Development & Automation for Cell Therapies Summit, you'll:
- Safeguard your program with comparability strategies built to satisfy FDA and EMA expectations.
- Apply automation and AI to predict process changes, reduce manual steps, and maintain product quality at scale.
- Navigate vendor selection confidently to avoid single-source dependency and protect your manufacturing pipeline long-term.
Unmissable Event Highlights
Automation in Action: From Individual Steps to End-to-End Process Integration
Manual processes introduce variability that can compromise your therapy's comparability and slow your path to scale. Discover how your peers are applying automation across manufacturing to aggregate process data, reduce human error, and keep your therapy consistent at every stage.
Hear from:
- Margot Molander, Process Development Scientist, Bristol Myers Squibb
- Sreedhar Thirumala, Director, Process Development, Genentech
- Yan Wang, Director, Head of Cellular Process Development, Regeneron
- Yan Li, Senior Director, Process Development, Cabaletta Bio
- Ben Schilling, Senior Manager, Process Development, Caribou Biosciences
In Vivo Cell Therapy: What Does Process Development Look Like When Manufacturing Happens in the Patient?
In vivo cell therapy offers lower costs, scalable manufacturing, and faster treatment. However, it raises entirely new process development challenges your team may not have encountered yet. Join this discussion to explore how optimized in vivo PD strategies could future-proof your pipeline.
Moderated by:
- Xiangming Li, Associate Director, Bioprocess Development, Cartesian Therapeutics
Learn What it Actually Takes to Get Cell Therapy to Market
Most programs don't fail due to clinical efficacythey fail in their process strategy. Discover how JW Therapeutics overcame comparability, technology transfer, and GMP execution challenges to achieve commercial approval for relma-cel in China, so your team can avoid the same pitfalls and get one step closer to your own commercialization milestone.
Hear from:
- Susan Sun, Associate Director, Process Development, JW Therapeutics
Explore the Full Event Guide
- Hear from 18+ expert speakers covering the full cell therapy development pipeline from early clinical to commercial.
- Gain 6+ hours of late and commercial stage presentations and panel discussions you can apply immediately.
- Connect and Network with 30% of speakers from Top 20 global biopharma companies.
- 65:35 autologous to allogeneic content split across two days.
- Gain the opportunity to Join exclusive roundtables on in vivo cell therapy process development to showcase how the process will adapt to future advances.
Attending Companies Include
Explore the Agenda
Two days of niche process development case studies, panel discussions, and workshops built exclusively for cell therapy PD teams.
Partner With Us
Put your solutions in front of senior process development decision-makers actively looking for them.
Join Biopharma Experts
Connect with the cell therapy process development community spanning early clinical to commercial stage across two days of dedicated networking.